Department of Pathology, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Pathobiology. 2013;80(1):32-40. doi: 10.1159/000339431. Epub 2012 Jul 24.
Breast cancer is a heterogeneous neoplasm. Distinct subtypes of breast cancer have been defined, suggesting the existence of molecular differences contributing to their clinical outcomes. However, the molecular differences between human epidermal growth factor receptor 2 (HER2)-positive and HER2-negative breast cancer tumors remain unclear. The aim of this study was to identify a gene expression profile for breast tumors based on their HER2 status.
The HER2 status was determined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in 54 breast tumor samples. Using Affymetrix microarray data from these breast tumors, we established the expression profiling of breast cancer based on HER2 IHC and FISH results. To validate microarray experiment data, real-time quantitative reverse transcription-PCR was performed.
We found significant differences between the HER2-positive and HER2-negative breast tumor samples, which included overexpression of HER2, other genes located on 17q12 and genes functionally related to migration.
Our study shows the potential of integrated genomic profiling to shed light on the molecular knowledge of HER2-positive breast tumors.
乳腺癌是一种异质性肿瘤。已经定义了不同类型的乳腺癌，这表明存在导致其临床结果差异的分子差异。然而，HER2 阳性和 HER2 阴性乳腺癌肿瘤之间的分子差异仍不清楚。本研究旨在根据 HER2 状态确定乳腺癌肿瘤的基因表达谱。
通过免疫组织化学（IHC）和荧光原位杂交（FISH）在 54 个乳腺癌肿瘤样本中确定 HER2 状态。使用来自这些乳腺癌肿瘤的 Affymetrix 微阵列数据，我们根据 HER2 IHC 和 FISH 结果建立了乳腺癌的表达谱。为了验证微阵列实验数据，进行了实时定量逆转录聚合酶链反应。
我们发现 HER2 阳性和 HER2 阴性乳腺癌肿瘤样本之间存在显著差异，包括 HER2 过表达、位于 17q12 上的其他基因以及与迁移功能相关的基因。
我们的研究表明，综合基因组分析有可能揭示 HER2 阳性乳腺癌肿瘤的分子知识。
